CalciMedica Stock to Reverse Split on Monday, August 31st (NASDAQ:CALC)

Posted by George Bondi on Aug 27th, 2026

CalciMedica Inc. (NASDAQ:CALC – Free Report) shares are set to reverse split on Monday, August 31st. The 1-5 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 30th.

CalciMedica Stock Performance

Shares of NASDAQ CALC traded down $0.12 during trading on Thursday, reaching $0.47. 1,490,454 shares of the stock traded hands, compared to its average volume of 335,053. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 1.67. CalciMedica has a 52-week low of $0.46 and a 52-week high of $7.20. The company has a 50-day moving average of $0.76 and a 200-day moving average of $0.70.

CalciMedica (NASDAQ:CALC – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.17). Research analysts anticipate that CalciMedica will post -1.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CALC has been the subject of several recent research reports. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Guggenheim initiated coverage on shares of CalciMedica in a research note on Thursday, August 20th. They issued a “buy” rating for the company. Wall Street Zen raised shares of CalciMedica to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings lowered CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. Finally, HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Get Our Latest Research Report on CALC

Insider Activity at CalciMedica

In related news, Director Fred A. Middleton acquired 248,972 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was bought at an average price of $0.80 per share, for a total transaction of $199,177.60. Following the completion of the purchase, the director directly owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. The trade was a 30.57% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 28.25% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC increased its stake in CalciMedica by 45.0% during the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after buying an additional 39,775 shares during the period. 180 Wealth Advisors LLC boosted its position in CalciMedica by 297.2% in the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after buying an additional 94,650 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after buying an additional 34,386 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of CalciMedica during the fourth quarter valued at about $506,000. Finally, PVG Asset Management Corp acquired a new stake in shares of CalciMedica during the fourth quarter valued at about $302,000.

CalciMedica Company Profile

(Get Free Report)

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.